Clinical trial · no report yet · Phase 3
LATIFY
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
- NCT05450692 ↗
- Active not recruiting
- AstraZeneca
- 3 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy: LATIFY
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- Ceralasertib; Durvalumab; Docetaxel
- Arms
- Group A: Ceralasertib plus durvalumab combination therapy · Experimental
- Group B: Docetaxel monotherapy · Active comparator
- Enrollment
- 594
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- AstraZeneca with Parexel
- Start
- Sep 15, 2022
- Primary completion
- Oct 6, 2025
- Results posted
- No
- Registry record
- NCT05450692 · updated Jul 13, 2026